Sept 22 (Reuters) - Bristol Myers Squibb ( BMY ) said on

Monday that it was planning to launch its schizophrenia

treatment, Cobenfy, in the UK in 2026 and that the pricing would

be similar to its U.S. list price.

The drug carries a list price of $1,850 a month or about

$22,500 annually in the United States.

Bristol said it planned to submit a marketing

authorisation application for Cobenfy to the UK medicines

regulator later this year, under a fast-track route.

The drug gained U.S. FDA approval last year and became

the first approved antipsychotic that targets cholinergic

receptors as opposed to dopamine receptors, which have long been

the standard of care.